Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 V116 vs PPSV23 in pneumococcal vaccine-naive Japanese adults ≥65 years
jRCT2031220551Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Serotype-specific OPA GMTs at Day 30 post-vaccination, Solicited adverse events and 1 more. Started Jan 2023; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2031220551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220551.